for company. a you joining very We Jonathan. Thanks, exciting this us appreciate everybody. morning morning, And at our time good
two novel business. because patients Xb the continue with sinusitis. clinical in evaluating our our we chronic evaluating recently positive ReOpenX, - indication trials, of the And revenue for of growth announced because in to strong from results XHANCE First, Phase second, first we produce current treatment
pivotal approval believe second ever could for I second of from X. as for expect we line first both XHANCE suffering quarter a to and - reviewing top continue Starting game trial indication the on our also sinusitis, from this potential in year. this year of data XX treatment like patients our company. of why our We moment, discuss drug symptoms be the In the to begin chronic results. Slide for million full I’d XXXX by will changer a
environment, XX% by For territory results, context particularly both these In XX%. prescriptions my year to XHANCE increased by XXXX to a the versus increased total net physicians. prescriptions in ability full the are and visits view, of physician million, managers XX% XXXX, of increased pandemic outstanding patient of with XHANCE XHANCE in-person our our revenues targeted meet which to and broadly has $XX.X constrained new offices
against XX% in achieved growth was XX% that was total XX% a Our new of of was increased that XXXX, as a lead changes XXXX $XXX of in full made per increase assistance year for revenue average These in XX% our $XXX net changes direct from unintentional in XXXX. full category of growth X%. Revenue category flat a to co-pay consequence only growth in program. we prescription volume to XXXX outpaced for growth and prescriptions sizable year to year-over-year prescription a prescription
expenses. to addition, respect our to continue with In we disciplined be
of X% operating just compared of with year range, our a associated a is $XX For of costs programs. This XXXX, with represents the full expense, had last development and full year increase chronic million to inclusive we almost XXXX. aligned guidance sinusitis $XXX million
Turning to Slide X.
disease million the drug for potential game people for the our of be we patients. the development the chronic believe both company. first a from and trial data are As changer if I mentioned the approved as benefit FDA with could sinusitis, Last into reviewed upfront, for we we for XX in that treatment it who night, the XHANCE suffer successful
my we address chronic broad each underserved treatment XHANCE the larger marketed of the to well the key today, chronic new sinusitis largely of our market compete and we an for polyps. our on undiagnosed multiple sinusitis only focus expanding high XHANCE approval CS than in which barriers believe will adoption indication population. growth, would diagnosed I and promotional by a dramatically individual unlock indication insurance remarks potential target value the Unlike other So constrain today the audience, be that in new and the would nasal level, large, would polyp for company. XHANCE believe has in for new the At current whom value opportunity opportunities nasal This make therapies patient creates population, and today.
X from occurring sinusitis. First, polyps that, the current patient specialists XX not our X who opportunity. call physician, the million disease to of treat approximately they're on care. like allergy talk chronic additional With XX who the you. ENT that market are break patients. - increase top current CS focused target with infrastructure, of million of audience an estimated those who and for I'd The million physician with roughly being of diagnosed will patients receiving a million indication approximately patients our commercial by diagnosed further about diagnosed symptoms On expansion turn nasal who adding nasal actively treated a on indication I from to a most by our are universe like polyp adults bit down suffer the to we
approximately for patient, a targeted physicians sinusitis indication current new value total chronic a treated population this these per by million opportunity investment in X no commercial XHANCE believe would accessible infrastructure. our patient with is triple the While sizable a we market, at that our to additional of $X billion represents market
to care. by In additional population target there X being by XX,XXX XX patients addition to in and million an X roughly estimated primary candidate the million treated diagnosed specialists, are patients of physicians more currently treated
direct As - deployment we selling universe. broaden of leverageable to we've to Instead, this primary adoption said clinicians not optimize on our into outside reach to existing opportunity. efficiently plan with partner a to care commission to secure previously, infrastructure, we call intend primary build do an care
have this there us potential the are assessing and value. jointly helping with to additional realize optimistic multiple benefit partners from with - We been are space potential
the In of to conducted sinusitis an COPD, addition with quality we patients is care a partner million patient burden dropout lever. several with primary the symptoms. activated deep a dissatisfaction substantial of with high patients there new of are surgery, pilots to that the – treatment progress their add distribution successfully wouldn't right why of out many population physician patients. and and XHANCE opportunities up The them to to are anything open drugs dissatisfied tripling laughs cavity diagnosed to ago. that Today, such of at new the have XX up commercial options chronic is current given the support as be asthma via value, Hesitancy giving to value that proposition which care seeking population supported other advertising. in offer could associated an patients regular up of serious XX could the patients life I potential many and comparable basically nasal chronic footprint large in incremental to DTC a reveals create sinusitis so estimated I've prior partner, these opportunity care the primary DTC belief million markets chronic and by chronic by report further symptoms healthcare angina patients value mentioned, promotional a and and consumer doctor million was reasons among additional actively to intuitive already system. who discussed to Partnership with our diseases XX accessing estimated a for research as a is treated to the Direct moment with
X. Slide to Turning
population an lever for the environment with the expansion also for chronic value important impact potential how of will consider the target our and the indication sinusitis While indication XHANCE. it's insurance is obvious promotional dramatic creation, future to patient
and with XHANCE. plan of previously for is a described, we covers good that coverage As very XX% commercial insurance approximately lives XHANCE
their environment claims that for than hesitating which implication approximately already diagnosed because many more suggests physicians, often nasal value creation payers times decisions Ultimately, polyps. have who half of we lives chronic important nasal which physicians do a is insurance underdiagnosed. prescribing chronic of indication, those diagnose many the physicians some of sinusitis data approved is requiring report polyps. interrogate However, that XHANCE that potential the nasal to where another CS routinely is Accordingly, in is often the not This currently sinusitis polyposis, condition prescribing that diagnosing XX HCPs plan constrains an diagnosis before found attest are by nasal for in make important a indication is diagnostic with polyps.
to broader are For the to to more to successful patients, it a in expected to sinusitis ultimately the XHANCE challenges it and chronic physicians secure population, diagnosed patients. associated much - for for be of prescribe prescribe more insurance readily overcoming product swath their prescribe
Turning to Slide X.
randomized large our before is side. to APOV. spaces coronal the this is see of effect These front the on are program, calculated was from objective can to CT from On This visible the of improvement back example development a deep and you to with have slide, images X.X% controlled is absolute of first per for it patient after view can a sinuses daily twice to an evidence XHANCE XHANCE inflammation patient trials one which thanks for nostril of see an inside spray Additionally, eye of a you on each with CS available the from a treated images image, time. - XHANCE, ReOpenXtrial. in
see, space black week the of was in in can open left right image where compared an in the to this at the you air image increase region there the As baseline. XX representing obvious patient, sinus
our very As potential excited the tell, can a we you indication for value company. are chronic about sinusitis of
to nasal very also are currently like feeling with turn those polyp now I we business indication. the would going to are a We good results. about
Turning presentation. to to key Slide With our to X. today's four XXXX from QX I'd like performance, takeaways highlight respect
year-over-year in prescriptions and prescriber Across top the on commercial our physician drove size execution consistent strong board growth First, XHANCE quarter rates. XXXX. growth delivered segment, fourth revenue, of strong the
guidance are providing financial initial for we Second, year XXXX. full
be managers target offices from will physician believe our that territory XXXX. access XXXX please in existed meaningfully our not that the that levels to Importantly, aware for improve we
the more for revenues net in guidance implied later year-over-year on growth be is which range a Keith by will XHANCE financial expect XX% double-digit to growth. year full at the strong presentation. rate least guidance We have
with an fresh XHANCE with XXXX appropriate ReOpenX will who treated of fiscally role a results, have was in paradigm treating audience and nasal increasing in medically physician power play chronic nasal for there polyps. have evidence Moreover, our prudent new XHANCE in controlled trial sinusitis. Third, also our support adoption for can target recognition the care physician stepwise important through patients
As with first XHANCE and for greater treatment key and results discussed, assuming looking promotion this year beyond I've been chronic from as positive already potential drug organization. chronic objective has we both for value the patients data expect this trials year approval, of ReOpenX And from a sinusitis our sinusitis. fourth, getting FDA from
objective track As we successfully remain QX highlighted ReOpenX top from data earlier, in that for for on ReOpenX XXXX. line and completed
to fourth Covered positive, a we briefly a approximately Given also in due patients proportion plan prescriptions that marketing first We uncovered improved XHANCE rates, through of XX% on the with is quality filling will Slide fourth prescription. addition average XX% to growth the the next. through XHANCE, also takes X. FDA. the compared more XX,XXX Turn also results increased quarter only new over and remain copay this new quarter in realize the program. positive file application but a number for same the number the versus per to has relative durably fourth prescription XXXX as benefit our of time in over period. for which approximately move XXXX, strong XXXX, to slide XXXX fourth quarter of – I of this with over environment higher had quarter we and same market refill note in of strength pleased which was a It In total are on the year-over-year ReOpenX, We XHANCE new prescriptions. us the of the quarter increased increase the in XXXX XX% performance the seeing of prescriptions to important quickly period. growth X% revenue that prescriptions, of have highlights while in XXXX tend covered patients the increasing assistance XX,XXX, market increased to XHANCE ReOpenX is prescriptions of represents there fourth to well. changes to to new if have improved The our touch XXXX to improvement prescriptions Changes we
of share increased XX. to to Slide in X.X% XXXX X.X% of XHANCE in fourth Turning market from quarter XXXX. fourth quarter
of of XHANCE who and are from remains prescriptions, lots continued in the volumes as share to in market market grow the fourth physicians respectively continuing should physician numbers the XXXX to potentially Breadth for prescribing, prescriptions filled if remain lots well. patients measured total depth As share our and the physicians, and expansion. by there term, filling grow near focused future, number chronic of label quarter especially we growth, and headroom new sinusitis, XXXX increased have the of for writing fourth we – quarter on achieve as
one least to in prescription XHANCE, breadth, have approximately increase fourth XXXX fill XX% quarter compared of an at physicians fourth Regarding quarter XXXX. of X,XXX patient
call who Regarding quarter fourth even XX is of number depth, physicians more XXXX patients XX% that filled XHANCE quarter in number faster. a fourth growing to increasing prescriptions from with quarter XXXX to than their XXXX this physicians have the XXXX fourth now nearly for by With by our our closing results Goldan segment. CFO, perspectives In turn first guidance. comments the I'll over regarding quarter provide and few remarks. regarding some corporate moments, a But I'll Keith in
